The platelet to lymphocyte ratio predicts overall survival better than the neutrophil to lymphocyte ratio in metastatic renal cell carcinoma.


Creative Commons License

Aktepe O. H., GÜner G., GÜven D. C., Şahİn T. K., ArdiÇ F. S., YÜce D., ...Daha Fazla

Turkish journal of medical sciences, cilt.51, ss.757-765, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51
  • Basım Tarihi: 2021
  • Doi Numarası: 10.3906/sag-2009-75
  • Dergi Adı: Turkish journal of medical sciences
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.757-765
  • Anahtar Kelimeler: NLR, PLR, metastatic renal cell carcinoma, prognosis, tyrosine kinase inhibitors, PRETREATMENT NEUTROPHIL, PROGNOSTIC VALUE, POOR-PROGNOSIS, CANCER, INFLAMMATION, INFILTRATION, ASSOCIATION, EXPRESSION, COHORT, GRADE
  • Hacettepe Üniversitesi Adresli: Hayır

Özet

Background/aim: The prognostic values of systemic inflammatory markers, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) on overall survival (OS) of metastatic renal cell carcinoma patients (mRCC) treated with tyrosine kinase inhibitors (TKI) remain unclear. Thus, the present study aimed to investigate the prognostic impact of these markers on OS of mRCC patients.